Allarity Therapeutics (ALLR) Reports Key Progress in Phase 2 Stenoparib Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
November 18, 2024 8:00 AM ESTof advanced ovarian cancer
Allarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparibs clinical development toward FDA approval Expansion of Allarity Medical Laboratory into revenue-generating services
for external biotech clients
Continued focus on advancing stenoparib to address
critical unmet needs in ovarian... More
